Sobre 4 señales de compra con un rendimiento T+90 consolidado. Base de rendimiento: cierre del día siguiente a la publicación.
Historial de señales
Explore the detailed record of transactions filed by Parker Geoffrey M., Director. Officer active across 6 companies, notably PERRIGO Co plc. Cumulatively, 37 disclosures have been published. Breakdown: 14 buys · 3 sells. Total volume traded: €1.1m. Activity tracked since 7 May 2021. The latest transaction was filed on 14 May 2026 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Parker Geoffrey M.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25.000 títulos@ 1,3896 €14.5% de su flujoCommon StockSEC:0000899243-22-022382:0
Salida canónica: 11 sept 2022 (T+90)
25 de 37 declaraciones
About Parker Geoffrey M.
Parker Geoffrey M. is Director at PERRIGO Co plc, Director at Better Therapeutics, Inc., Director at ChemoCentryx, Inc., Chief Financial Officer at Allogene Therapeutics, Inc., and COO, CFO and EVP at Tricida, Inc. He has 37 filings in total. In the recent filings available, covering the period from 2016-01-11 to 2026-05-15, buys amount to EUR 998861 and sells to EUR 82811, with a modal transaction nature listed as Acquisition.